Ocular Hypertension

🩺What is Ocular Hypertension?

The Ocular Hypertension Treatment Study (OHTS, 2002, NEJM) was a landmark multicenter randomized clinical trial that established the benefit of IOP-lowering therapy in preventing or delaying the onset of primary open-angle glaucoma (POAG) in patients with ocular hypertension (IOP 24-32 mmHg). The study followed 1,636 patients for a mean of 72 months and identified baseline risk factors that predict conversion to glaucoma. The European Glaucoma Prevention Study (EGPS, 2005) independently validated these risk factors. The combined OHTS/EGPS model includes: age (older age increases risk), intraocular pressure (higher baseline IOP increases risk), central corneal thickness (thinner CCT = higher risk), baseline visual field pattern standard deviation (PSD >2 dB = higher risk), vertical cup-to-disc ratio (larger CDR = higher risk), and race (Black American or African Caribbean ethnicity increases risk). Diabetes was also independently associated with increased risk in pooled analysis. The risk calculator was externally validated in multiple populations including the Diagnostic Innovations in Glaucoma Study (DIGS). Clinically, a 5-year risk threshold of >15% is commonly used as a trigger for initiating IOP-lowering treatment in patients with ocular hypertension, as recommended by the AAO Preferred Practice Pattern for Primary Open-Angle Glaucoma (2020).

🏥Signs & Symptoms

The following clinical signs and symptoms are commonly assessed when evaluating Ocular Hypertension:

• Visual Field PSD Pattern Deviation
• Race/Ethnicity
• Diabetes

🔬Causes & Etiology

The Ocular Hypertension Treatment Study (OHTS, 2002, NEJM) was a landmark multicenter randomized clinical trial that established the benefit of IOP-lowering therapy in preventing or delaying the onset of primary open-angle glaucoma (POAG) in patients with ocular hypertension (IOP 24-32 mmHg). The study followed 1,636 patients for a mean of 72 months and identified baseline risk factors that predict conversion to glaucoma. The European Glaucoma Prevention Study (EGPS, 2005) independently validated these risk factors. The combined OHTS/EGPS model includes: age (older age increases risk), intraocular pressure (higher baseline IOP increases risk), central corneal thickness (thinner CCT = higher risk), baseline visual field pattern standard deviation (PSD >2 dB = higher risk), vertical cup-to-disc ratio (larger CDR = higher risk), and race (Black American or African Caribbean ethnicity increases risk). Diabetes was also independently associated with increased risk in pooled analysis. The risk calculator was externally validated in multiple populations including the Diagnostic Innovations in Glaucoma Study (DIGS). Clinically, a 5-year risk threshold of >15% is commonly used as a trigger for initiating IOP-lowering treatment in patients with ocular hypertension, as recommended by the AAO Preferred Practice Pattern for Primary Open-Angle Glaucoma (2020).

⚠️Risk Factors

The following factors are known to increase the risk of developing or worsening Ocular Hypertension:

• Age (years)
• Intraocular Pressure (mmHg)
• Central Corneal Thickness (µm)
• Vertical Cup-to-Disc Ratio (0-1)

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Ocular Hypertension:

• Glaucoma Risk Calculator (OHTS/EGPS)

  The glaucoma risk calculator estimates the 5-year probability of developing primary open-angle glaucoma in patients with ocular hypertension, based on risk factors from the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS).

🧬Diagnostic Logic & Scoring Breakdown

The risk calculation integrates multiple weighted risk factors from the OHTS/EGPS pooled analysis. Age >40 years increases baseline risk by approximately 2% per decade. Baseline IOP >22 mmHg contributes approximately 8% risk per mmHg above 22. Central corneal thickness <555 µm contributes approximately 1.2% risk per 10 µm below 555. Abnormal PSD pattern deviation on baseline visual field testing adds approximately 10% risk. Vertical cup-to-disc ratio >0.5 adds approximately 30% risk per 0.1 above 0.5. Black/African-Caribbean race adds approximately 15% risk. Diabetes adds approximately 8% risk. The total risk is capped at 100%.

📢Clinical Significance & Implications

The OHTS/EGPS risk calculator is the most validated tool for predicting glaucoma onset in ocular hypertension. Its practical applications include: (1) Shared decision-making — providing patients with their personalized 5-year risk helps them understand the benefits of treatment vs observation. A patient with 40% 5-year risk who chooses observation has a number-needed-to-treat of approximately 10 to prevent one case of glaucoma. (2) Treatment threshold — most guidelines use >15% 5-year risk as a treatment trigger. (3) Resource allocation — identifies high-risk patients needing more frequent monitoring. (4) Clinical trial inclusion — the calculator is used to enrich clinical trial populations with higher-risk patients. OHTS showed that treatment reduced 5-year glaucoma incidence from 9.5% to 4.4% in the overall population, but the absolute risk reduction was much higher (15-20%) in high-risk subgroups.

🛡️Prevention & Management

Evidence-based prevention and management strategies for Ocular Hypertension include:

• Annual eye examinations. Maintain healthy lifestyle. Monitor for symptoms.
• Consider IOP-lowering therapy. Monitor every 6-12 months. Baseline optic nerve imaging.
• Initiate IOP-lowering therapy. Monitor every 3-6 months with optic nerve imaging and visual fields.
• The AAO Preferred Practice Pattern recommends considering treatment when 5-year risk exceeds 15% on the OHTS/EGPS calculator, or when IOP >30 mmHg regardless of risk. Treatment benefit is proportional to baseline risk — patients with higher baseline risk derive greater absolute benefit from IOP-lowering therapy.

💡 Clinical Assessment Scenario Example

A 62-year-old Black American male with ocular hypertension (IOP 26 mmHg in both eyes). CCT: 540 µm. Vertical CDR: 0.6. Visual fields show PSD pattern deviation. No diabetes. 5-year glaucoma risk: ~48%. Interpretation: High risk. Recommendation: Initiate IOP-lowering therapy with topical prostaglandin analog. Close monitoring with optic nerve imaging and visual fields every 6 months.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Ocular Hypertension:

🔗Related Diseases & Conditions

These conditions are clinically associated with Ocular Hypertension through shared risk-scoring calculators and assessment tools:

• Primary Open-Angle Glaucoma

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Using the calculator for patients with established glaucoma

  ✅ Correction: This risk calculator is designed for patients with ocular hypertension (IOP >21 mmHg) without evidence of glaucomatous optic neuropathy or visual field loss. Patients with established glaucoma should be managed according to glaucoma severity staging and target IOP levels, not this risk calculator.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Ocular Hypertension; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References